Related Experiment Video
Updated: Aug 19, 2026

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas
Shuangmei Tong1, Ying Wang1, Jian Wu1
1Department of Pharmacy, Huashan Hospital, Fudan University School of Medicine, Shanghai, 200040, China.
Abstract:
Recent developments in pharmacogenomics have created opportunities for predicting temozolomide response in gliomas. Temozolomide is the main first-line alkylating chemotherapeutic drug together with radiotherapy as standard treatments of high-risk gliomas after surgery. However, there are great individual differences in temozolomide response. Besides the heterogeneity of gliomas, pharmacogenomics relevant genetic polymorphisms can not only affect pharmacokinetics of temozolomide but also change anti-tumor effects of temozolomide. This review will summarize pharmacogenomic studies of temozolomide in gliomas which can lay the foundation to personalized chemotherapy.
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

